Author： Sita-Lumsden Ailsa Fletcher Claire E Dart D Alwyn Brooke Greg N Waxman Jonathan Bevan Charlotte L
Publisher： Future Medicine
ISSN： 1752-0363
Source： Biomarkers in Medicine, Vol.7, Iss.6, 2013-12, pp. : 867-877
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Prostate cancer, the most common cancer of western men, requires new biomarkers, especially given that the benefits of PSA testing remain uncertain. Nucleic acids can now be accurately and sensitively detected in human blood. Over the last decade, investigations into utility of circulating cell-free miRNA, DNA and mRNA as novel biomarkers have expanded exponentially. In the near future, they may be routinely used to accurately diagnose cancers, stratify indolent from aggressive disease and inform treatment decisions. However, advancement of such tests into clinical settings is hampered by technical problems with assay specificity and sensitivity, and small study sizes. This review highlights the different forms of circulating nucleic acids and those that show the most potential as viable biomarkers for prostate cancer.
Related content
Access to resources
Recommend
Prevalence of Circulating Tumor Cells in Localized Prostate Cancer
Current Urology, Vol. 7, Iss. 2, 2013-10 ,pp. :